User:NickCT/LixiLan: Difference between revisions
m cat |
speedy |
||
| Line 1: | Line 1: | ||
{{db-promo| Blatant advertisement for this drug candidate. Hype much? [[User:Jytdog|Jytdog]] ([[User talk:Jytdog|talk]]) 22:52, 19 September 2016 (UTC)}} |
|||
{{Orphan|date=September 2016}} |
{{Orphan|date=September 2016}} |
||
'''LixiLan''' is the [[trade name]] of a drug being developed by [[Sanofi]] for treatment of diabetes. The drug is a [[combination therapy]] and combines the two diabetes drugs [[insulin glargine]] and [[lixisenatide]].<ref>{{cite press release|date=12 June 2016|title=SANOFI ANNOUNCES POSITIVE PHASE 3 RESULTS FOR INVESTIGATIONAL TITRATABLE FIXED-RATIO COMBINATION OF INSULIN GLARGINE AND LIXISENATIDE|url=http://www.news.sanofi.us/2016-06-12-Sanofi-Announces-Positive-Phase-3-Results-for-Investigational-Titratable-Fixed-Ratio-Combination-of-Insulin-Glargine-and-Lixisenatide|location= |publisher=[[Sanofi]]|access-date=2016-09-19}}</ref> In 2016 Sanofi announced the drug had produced positive results in Phase III [[Clinical trial|clinical trail]]s and suggested that the drug would be approved by the [[Food and Drug Administration]] in 2017.<ref>{{cite news |last=Blamont|first=Matthias|date=12 June 2016|title=Sanofi says LixiLan diabetes drug trials meet targets|url=http://www.reuters.com/article/us-sanofi-diabetes-idUSKCN0YY10F|newspaper=[[Reuters]]|access-date=19 September 2016}}</ref> |
'''LixiLan''' is the [[trade name]] of a drug being developed by [[Sanofi]] for treatment of diabetes. The drug is a [[combination therapy]] and combines the two diabetes drugs [[insulin glargine]] and [[lixisenatide]].<ref>{{cite press release|date=12 June 2016|title=SANOFI ANNOUNCES POSITIVE PHASE 3 RESULTS FOR INVESTIGATIONAL TITRATABLE FIXED-RATIO COMBINATION OF INSULIN GLARGINE AND LIXISENATIDE|url=http://www.news.sanofi.us/2016-06-12-Sanofi-Announces-Positive-Phase-3-Results-for-Investigational-Titratable-Fixed-Ratio-Combination-of-Insulin-Glargine-and-Lixisenatide|location= |publisher=[[Sanofi]]|access-date=2016-09-19}}</ref> In 2016 Sanofi announced the drug had produced positive results in Phase III [[Clinical trial|clinical trail]]s and suggested that the drug would be approved by the [[Food and Drug Administration]] in 2017.<ref>{{cite news |last=Blamont|first=Matthias|date=12 June 2016|title=Sanofi says LixiLan diabetes drug trials meet targets|url=http://www.reuters.com/article/us-sanofi-diabetes-idUSKCN0YY10F|newspaper=[[Reuters]]|access-date=19 September 2016}}</ref> |
||
Revision as of 22:52, 19 September 2016
| This user page may meet Wikipedia's criteria for speedy deletion because in its current form it serves only to promote or publicise an entity, person, product, or idea, and would require a fundamental rewrite in order to become encyclopedic. See the [[ Blatant advertisement for this drug candidate. Hype much? Jytdog (talk) 22:52, 19 September 2016 (UTC)|previous discussion]]. However, the mere fact that a company, organization, or product is a page's subject does not, on its own, qualify that page for deletion under this criterion. This criterion also does not apply where substantial encyclopedic content would remain after removing the promotional material as deletion is not cleanup; in this case please remove the promotional material yourself, or add the {{advert}} tag to alert others to do so. See CSD G11.
If this user page does not meet the criteria for speedy deletion, or you intend to fix it, please remove this notice, but do not remove this notice from pages that you have created yourself. If you created this page and you disagree with the given reason for deletion, you can click the button below and leave a message explaining why you believe it should not be deleted. You can also visit the talk page to check if you have received a response to your message. Note that this user page may be deleted at any time if it unquestionably meets the speedy deletion criteria, or if an explanation posted to the talk page is found to be insufficient.
Note to page author: you have not edited the talk page yet. If you wish to contest this speedy deletion, clicking the button above will allow you to leave a talk page message explaining why you think this page should not be deleted. If you have already posted to the talk page but this message is still showing up, try purging the page cache. This page was last edited by Jytdog (contribs | logs) at 22:52, 19 September 2016 (UTC) (7 years ago) |
LixiLan is the trade name of a drug being developed by Sanofi for treatment of diabetes. The drug is a combination therapy and combines the two diabetes drugs insulin glargine and lixisenatide.[1] In 2016 Sanofi announced the drug had produced positive results in Phase III clinical trails and suggested that the drug would be approved by the Food and Drug Administration in 2017.[2]
References
- ^ "SANOFI ANNOUNCES POSITIVE PHASE 3 RESULTS FOR INVESTIGATIONAL TITRATABLE FIXED-RATIO COMBINATION OF INSULIN GLARGINE AND LIXISENATIDE" (Press release). Sanofi. 12 June 2016. Retrieved 2016-09-19.
- ^ Blamont, Matthias (12 June 2016). "Sanofi says LixiLan diabetes drug trials meet targets". Reuters. Retrieved 19 September 2016.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |